Compositions and methods of use for MGD-CSF in disease treatment

US8575312B2 · kind B2 · utility

Assignee

• Five Prime Therapeutics, Inc. · US

Inventors

• Dirk Behrens · San Francisco, US
• Elizabeth Bosch · Cupertino, US
• Stephen K. Doberstein · San Francisco, US
• Robert F. Halenbeck · San Rafael, US
• Kevin Hestir · Kensington, US
• Min Mei Huang · San Francisco, US
• Ernestine Lee · Kensington, US
• Haishan Lin · Richmond, US
• Thomas Linnemann · San Francisco, US
• Shannon Marshall · San Francisco, US
• Justin Wong · Oakland, US
• Ge Wu · Tustin, US
• Aileen Zhou · San Leandro, US
• Cindy Leo · San Francisco, US
• Lewis T. Williams · San Francisco, US

Key dates

• Filing date: Apr 13, 2012
• Grant date: Nov 5, 2013
• Expiry date: Apr 13, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.